参考文献/References:
[1] Bourekas EA,ShahR.etal intraarterial thrombolytic therapy with in 3 hours of the onset of stroke[J].Neurosurgery,2004,54(1):39-44.
[2] Berger C,Fiorelli M,Steiner T,et al.Hemorrhagic transformation of ischemic brain tissue-Asymptomatic or symptomatic?[J].Stroke,2001,32(6):1330-1335.
[3] Gilligan AK,Markus R,Read S,et al.Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke[J].Stroke,2002,33(9):2236-2242.
[4] Motto C,Ciccone A,Aritzu E,et al.Hemorrhage after an acute ischemic stroke[J].Stroke,1999,30(4):761-764.
[5] Fioelli M,Bastranello S,Von Kummer R,et al.Hemorrhagic transformation within 36 hours of a cerebral infarct:relationship with early clinical deterioration and 3-month ouiconle in the European cooperative acute stroke study I(ECASSI)[J].Stroke,1999,30(11):2283.
[6] Hacke W,Kaste M,Fiesehi C,et al.Randomised double-blind placebo-eontrolled trial of thrombolytic therapy with intravenousal teplase in acute stroke(ECASSll)isehemic Lancet[Z],1998:352.
[7] Paciaroni M,Agnelli G,Corea F,et al.Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study[J].Stroke,2008,39(8):2249-2256.
[8] Turner RJ,Sharp FR.Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke[J].Front Cell Neurosci,2016,4(10):56.
[9] Wang X,Lee SR,Arai K,et al.Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator[J].Nat Med,2003,9(10):1313-1317.
[10] Wang X,Tsuji K,Lee SR,et al.Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke[J].Stroke,2004,35(11 Suppl 1):2726-2730.
[11] Tan S,Wang D,Liu M,et al.Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis[J].J Neurol,2014,261(5):905-912.
[12] Terruso V,D'amelio M,Di Benedetto N,et al.Frequency and determinants for hemorrhagic transformation of cerebral infarction[J].Neuroepidemiology,2009,33(3):261-265.
[13] Wang BG,Yang N,Lin M,et al.Analysis of risk factors of hemorrhagic transformation after acute ischemic stroke: cerebral microbleeds do not correlate with hemorrhagic transformation[J].Cell Biochem Biophys,2014,70(1):135-142.
[14] Liu K,Yan S,Zhang S,et al.Systolic blood pressure variability is associated with severe hemorrhagic transformation in the early stage after thrombolysis[Z],2016.
[15] Bang OY,Buck BH,Saver JL,et al.Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging[J].Ann Neurol,2007,62(2):170-176.
[16] Kassner A,Roberts TP,Moran B,et al.Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: an Mr imaging permeability study[J].AJNR Am J Neuroradiol,2009,30(10):1864-1869.
[17] LarrueV,vonKummmerRR,MǜllerA,etal.Risk factors for severe hemorrhagic transformationin ischemic stroke patients treated with recombinant tissue plasminogen activator a secondary Analysis of the European-Australasian Acute Stroke Study(ECASSⅡ)[J].Stroke,2001,32(2):438-441.
[18] Zhang Y, Wang Y, Zuo Z, et al. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke[J]. J Neurol Sci,2014,347(1-2):148-154.
[19] Levy DE, Brott TG, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke[J]. Stroke,1994,25(2):291-297.
[20] 帅杰·急性卒中的静脉溶栓治疗新证据、新思考[J]·国际脑血管病杂志,2009,17(11):802.
[21] Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey[J]. Circulation, 2002,105(14):1679-1685.
[22] Hafez S, Abdelsaid M, El-Shafey S, et al. Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke[J]. Stroke, 2016,47(3):843-851.
[23] Xing Y, Guo ZN, Yan S, et al. Increased globulin and its association with hemorrhagic transformation in patients receiving intra-arterial thrombolysis therapy[J]. NeurosciBull, 2014,30(3):469-476.
[24] Mendioroz M, Fernández-Cadenas I, Alvarez-Sabín J, et al. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients[J]. Cerebrovasc Dis, 2009,28(2):143-150.
[25] Millan M, Sobrino T, Castellanos M, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke[J]. Stroke,2007,38(1):90-95.
[26] 袁文肖·血浆纤维连接蛋白与急性缺血性卒中患者出血性转化的相关性[J]·国际脑血管病杂志,2012,20(3):162.
[27] Brouns R,Heylen E,Sheorajpanday R,et al. Carboxypeptidate U( TAFIa)decreases the efficacy of thrombolytic therapy in ischemic stroke patients[J]. Clin Neurol Neurosurg,2009,111(2): 165-170.
[28] 龙洁,曲辉,白云,等. 脑血栓形成患者血浆组织纤溶酶原激活物及其快速抑制物的变化及临床意义[J]. 中华神经科杂志,1998,31( 5): 267-270.
[29] Montaner J,Ribo M,Monasterio J, et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke[J]. Stroke,2003,34(4): 1038-1040.
[30] 孙威,杨颖,李雪媛,等. 血浆中PAI-1和TAFI水平与溶栓后出血性转化相关性研究[J]. 中风与神经疾病杂志,2012,29(8):722-725.
[31] Zou M, Churilov L, He A, et al. Hyperdense middle cerebral artery sign is associated with increased risk of hemorrhagic transformation after intravenous thrombolysis for patients with acute ischaemic stroke. J Clin Neurosci, 2013,20(7):984-987.
[32] Kim EY, Kim SS, Na DG, et al. Sulcal hyperintensity on fluid-attenuated inversion recovery imaging in acute ischemic stroke patients treated with intra-arterial thrombolysis: iodinated contrast media as its possible cause and the association with hemorrhagic transformation[J]. J Comput Assist Tomogr, 2005,29(2):264-269.
[33] Morita N,Harada M,unoM,et al.Ischemic findings of T2※-weighted 3-tesla MRI in acute stroke patients[J].Cerebrovasc Dis,2008,26(4):367-375.
[34] Terasawa Y, Yamamoto N, Morigaki R, et al. Brush sign on 3-T T2*-weighted MRI as a potential predictor of hemorrhagic transformation after tissue plasminogen activator therapy[J]. Stroke, 2014,45(1):274-276
[35] Wang W, Li M, Wang Y, et al. GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats[J]. Mol Neurobiol, 2015,53(10):7028-7036.
[36] Lin Y, Xu M, Wan J, et al. Docosahexaenoic acid attenuates hyperglycemia-enhanced hemorrhagic transformation after transient focal cerebral ischemia in rats[J]. Neuroscience, 2015,301(20):471-479.
[37] Ito A, Niizuma K, Shimizu H, et al. SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occlusion under warfarin anticoagulation in mice[J]. Brain Res, 2014,1578(26):38-48.